schliessen

Filtern

 

Bibliotheken

Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator

Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). It is not clear how much of the edema is due to hydrodynamic changes from the obstruction and how much is due to chemical mediators. Patients with macular ede... Full description

Journal Title: Molecular Therapy 2008, Vol.16(4), p.791
Main Author: Peter A Campochiaro
Other Authors: Gulnar Hafiz , Syed Mahmood Shah , Quan Dong Nguyen , Howard Ying , Diana V Do , Edward Quinlan , Ingrid Zimmer-Galler , Julia A Haller , Sharon D Solomon , Jennifer U Sung , Yasmin Hadi , Kashif A Janjua , Nida Jawed , David F Choy , Joseph R Arron
Format: Electronic Article Electronic Article
Language:
Subjects:
ID: ISSN: 1525-0016 ; E-ISSN: 1525-0024 ; DOI: 10.1038/mt.2008.10
Link: http://dx.doi.org/10.1038/mt.2008.10
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: nature_a10.1038/mt.2008.10
title: Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator
format: Article
creator:
  • Peter A Campochiaro
  • Gulnar Hafiz
  • Syed Mahmood Shah
  • Quan Dong Nguyen
  • Howard Ying
  • Diana V Do
  • Edward Quinlan
  • Ingrid Zimmer-Galler
  • Julia A Haller
  • Sharon D Solomon
  • Jennifer U Sung
  • Yasmin Hadi
  • Kashif A Janjua
  • Nida Jawed
  • David F Choy
  • Joseph R Arron
subjects:
  • Antibodies, Monoclonal -- Therapeutic Use
  • Macular Edema -- Drug Therapy
  • Retinal Vein Occlusion -- Drug Therapy
  • Vascular Endothelial Growth Factor A -- Biosynthesis
ispartof: Molecular Therapy, 2008, Vol.16(4), p.791
description: Macular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). It is not clear how much of the edema is due to hydrodynamic changes from the obstruction and how much is due to chemical mediators. Patients with macular edema due to CRVO (n = 20) or BRVO (n = 20) were randomized to receive three monthly injections of 0.3 or 0.5 mg of ranibizumab. At the primary endpoint, month 3, the median improvement in letters read at 4 m was 17 in the 0.3-mg group and 14 in the 0.5-mg group for CRVO, and 10 and 18, respectively for the BRVO group. Optical coherence tomography (OCT) showed that compared to injections of 0.3 mg, injections of 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections, but in 3 months, excess central retinal thickening which is a quantitative assessment of the macular edema, was reduced by approximately 90% in all four treatment groups. There was no correlation between the amount of improvement and duration of disease or patient age at baseline, but there was some correlation between the aqueous vascular endothelial growth factor (VEGF) level at baseline and amount of improvement. These data indicate that excess production of VEGF in the retinas of patients with CRVO or BRVO is a major contributor to macular edema and suggest that additional studies investigating the efficacy of intraocular injections of ranibizumab are needed.
language:
source:
identifier: ISSN: 1525-0016 ; E-ISSN: 1525-0024 ; DOI: 10.1038/mt.2008.10
fulltext: fulltext
issn:
  • 1525-0016
  • 15250016
  • 1525-0024
  • 15250024
url: Link


@attributes
ID542955964
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1038/mt.2008.10
sourceidnature_a
recordidTN_nature_a10.1038/mt.2008.10
sourcesystemOther
pqid70426368
display
typearticle
titleRanibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator
creatorPeter A Campochiaro ; Gulnar Hafiz ; Syed Mahmood Shah ; Quan Dong Nguyen ; Howard Ying ; Diana V Do ; Edward Quinlan ; Ingrid Zimmer-Galler ; Julia A Haller ; Sharon D Solomon ; Jennifer U Sung ; Yasmin Hadi ; Kashif A Janjua ; Nida Jawed ; David F Choy ; Joseph R Arron
ispartofMolecular Therapy, 2008, Vol.16(4), p.791
identifier
source
subjectAntibodies, Monoclonal -- Therapeutic Use ; Macular Edema -- Drug Therapy ; Retinal Vein Occlusion -- Drug Therapy ; Vascular Endothelial Growth Factor A -- Biosynthesis;
descriptionMacular edema is a major cause of vision loss in patients with central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO). It is not clear how much of the edema is due to hydrodynamic changes from the obstruction and how much is due to chemical mediators. Patients with macular edema due to CRVO (n = 20) or BRVO (n = 20) were randomized to receive three monthly injections of 0.3 or 0.5 mg of ranibizumab. At the primary endpoint, month 3, the median improvement in letters read at 4 m was 17 in the 0.3-mg group and 14 in the 0.5-mg group for CRVO, and 10 and 18, respectively for the BRVO group. Optical coherence tomography (OCT) showed that compared to injections of 0.3 mg, injections of 0.5 mg of ranibizumab tended to cause more rapid reductions of central retinal thickening that lasted longer between injections, but in 3 months, excess central retinal thickening which is a quantitative assessment of the macular edema, was reduced by approximately 90% in all four treatment groups. There was no correlation between the amount of improvement and duration of disease or patient age at baseline, but there was some correlation between the aqueous vascular endothelial growth factor (VEGF) level at baseline and amount of improvement. These data indicate that excess production of VEGF in the retinas of patients with CRVO or BRVO is a major contributor to macular edema and suggest that additional studies investigating the efficacy of intraocular injections of ranibizumab are needed.
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
backlink$$Uhttp://dx.doi.org/10.1038/mt.2008.10$$EView_this_record_in_Nature
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Peter A Campochiaro
1Gulnar Hafiz
2Syed Mahmood Shah
3Quan Dong Nguyen
4Howard Ying
5Diana V Do
6Edward Quinlan
7Ingrid Zimmer-Galler
8Julia A Haller
9Sharon D Solomon
10Jennifer U Sung
11Yasmin Hadi
12Kashif A Janjua
13Nida Jawed
14David F Choy
15Joseph R Arron
titleRanibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator
general
0Nature Publishing Group
110.1038/mt.2008.10
2nature.com (Nature Publishing Group)
sourceidnature_a
recordidnature_a10.1038/mt.2008.10
issn
01525-0016
115250016
21525-0024
315250024
rsrctypearticle
creationdate2008
searchscopenature_a
scopenature_a
lsr30VSR-Enriched:[subject, pqid, eissn, pages, description]
sort
titleRanibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator
authorPeter A Campochiaro ; Gulnar Hafiz ; Syed Mahmood Shah ; Quan Dong Nguyen ; Howard Ying ; Diana V Do ; Edward Quinlan ; Ingrid Zimmer-Galler ; Julia A Haller ; Sharon D Solomon ; Jennifer U Sung ; Yasmin Hadi ; Kashif A Janjua ; Nida Jawed ; David F Choy ; Joseph R Arron
creationdate20080205
facets
frbrgroupid3452726340187408085
frbrtype5
creationdate2008
collectionnature.com (Nature Publishing Group)
prefilterarticles
rsrctypearticles
creatorcontrib
0Peter A Campochiaro
1Gulnar Hafiz
2Syed Mahmood Shah
3Quan Dong Nguyen
4Howard Ying
5Diana V Do
6Edward Quinlan
7Ingrid Zimmer-Galler
8Julia A Haller
9Sharon D Solomon
10Jennifer U Sung
11Yasmin Hadi
12Kashif A Janjua
13Nida Jawed
14David F Choy
15Joseph R Arron
jtitleMolecular Therapy
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Peter A Campochiaro
1Gulnar Hafiz
2Syed Mahmood Shah
3Quan Dong Nguyen
4Howard Ying
5Diana V Do
6Edward Quinlan
7Ingrid Zimmer-Galler
8Julia A Haller
9Sharon D Solomon
10Jennifer U Sung
11Yasmin Hadi
12Kashif A Janjua
13Nida Jawed
14David F Choy
15Joseph R Arron
atitleRanibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator
jtitleMolecular Therapy
risdate20080205
volume16
issue4
spage791
issn1525-0016
genrearticle
ristypeJOUR
pubNature Publishing Group
doi10.1038/mt.2008.10
pages791-799
eissn15250024
date2008-02-05